Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Liver Diseases

Free Subscription Articles published in N Engl J Med Retrieve available abstracts of 59 articles: HTML format

Single Articles

May 2024
1. HARRISON SA, Taub R
   A Phase 3 Trial of Resmetirom in NASH with Liver Fibrosis. Reply.
   N Engl J Med. 2024;390:1632-1633.
   PubMed    
   
   
   
2. SABET A
   A Phase 3 Trial of Resmetirom in NASH with Liver Fibrosis.
   N Engl J Med. 2024;390:1632.
   PubMed    
   
   
   February 2024
3. SCHNABL B
   PPAR Agonists in Primary Biliary Cholangitis.
   N Engl J Med. 2024;390:855-858.
   PubMed    
   
   
   
4. HIRSCHFIELD GM, Bowlus CL, Mayo MJ, Kremer AE, et al
   A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis.
   N Engl J Med. 2024;390:783-794.
   PubMed     Abstract available
   
   
   
5. ASSIS DN
   Advancing Second-Line Treatment for Primary Biliary Cholangitis.
   N Engl J Med. 2024;390:853-854.
   PubMed    
   
   
   
6. CUSI K
   Selective Agonists of Thyroid Hormone Receptor Beta for the Treatment of NASH.
   N Engl J Med. 2024;390:559-561.
   PubMed    
   
   
   
7. HARRISON SA, Bedossa P, Guy CD, Schattenberg JM, et al
   A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.
   N Engl J Med. 2024;390:497-509.
   PubMed     Abstract available
   
   
   December 2023
8. CAI S, Kuang M
   Clonorchis sinensis Liver Flukes.
   N Engl J Med. 2023;389:e57.
   PubMed    
   
   
   
9. LOOMBA R, Mansbach H, Margalit M
   Randomized Trial of Pegozafermin in NASH. Reply.
   N Engl J Med. 2023;389:2210.
   PubMed    
   
   
   
10. PATOULIAS D
    Randomized Trial of Pegozafermin in NASH.
    N Engl J Med. 2023;389:2209-2210.
    PubMed    
    
    
    November 2023
11. ROBBINS J, Halegoua-DeMarzio D, Basu Mallick A, Vijayvergia N, et al
    Liver Transplantation in a Woman with Mahvash Disease.
    N Engl J Med. 2023;389:1972-1978.
    PubMed     Abstract available
    
    
    
12. KOWDLEY KV, Bowlus CL, Levy C, Akarca US, et al
    Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis.
    N Engl J Med. 2023 Nov 13. doi: 10.1056/NEJMoa2306185.
    PubMed     Abstract available
    
    
    September 2023
13. RINELLA ME
    Pegozafermin for NASH - A Sprint to Start a Marathon.
    N Engl J Med. 2023;389:1044-1046.
    PubMed    
    
    
    
14. LOOMBA R, Sanyal AJ, Kowdley KV, Bhatt DL, et al
    Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH.
    N Engl J Med. 2023;389:998-1008.
    PubMed     Abstract available
    
    
    
15. ROBERTS EA, Schilsky ML
    Current and Emerging Issues in Wilson's Disease.
    N Engl J Med. 2023;389:922-938.
    PubMed    
    
    
    August 2023
16. VALLA DC, Garcia-Pagan JC
    Primary Budd-Chiari Syndrome. Reply.
    N Engl J Med. 2023;389:10.
    PubMed    
    
    
    
17. BORSANI O, Pietra D, Rumi E
    Primary Budd-Chiari Syndrome.
    N Engl J Med. 2023;389:10.
    PubMed    
    
    
    July 2023
18. DAUVILLIERS Y, Mignot E, Del Rio Villegas R, Du Y, et al
    Oral Orexin Receptor 2 Agonist in Narcolepsy Type 1.
    N Engl J Med. 2023;389:309-321.
    PubMed     Abstract available
    
    
    June 2023
19. BALWANI M, Desnick RJ, Belongie K
    Dersimelagon in Erythropoietic Protoporphyrias. Reply.
    N Engl J Med. 2023;388:2492-2493.
    PubMed    
    
    
    
20. BARMAN-AKSOZEN J, Langendonk JG
    Dersimelagon in Erythropoietic Protoporphyrias.
    N Engl J Med. 2023;388:2492.
    PubMed    
    
    
    
21. GRANATA F, Dechant C, Falchetto R
    Dersimelagon in Erythropoietic Protoporphyrias.
    N Engl J Med. 2023;388:2491-2492.
    PubMed    
    
    
    April 2023
22. BALWANI M, Bonkovsky HL, Levy C, Anderson KE, et al
    Dersimelagon in Erythropoietic Protoporphyrias.
    N Engl J Med. 2023;388:1376-1385.
    PubMed     Abstract available
    
    
    
23. GARCIA-PAGAN JC, Valla DC
    Primary Budd-Chiari Syndrome.
    N Engl J Med. 2023;388:1307-1316.
    PubMed    
    
    
    February 2023
24. NADIM MK, Garcia-Tsao G
    Acute Kidney Injury in Patients with Cirrhosis.
    N Engl J Med. 2023;388:733-745.
    PubMed    
    
    
    
25. BHAN I, Schaefer EA, Bradley WR, Rodriguez-Lopez JM, et al
    Case 4-2023: A 56-Year-Old Man with Abnormal Results on Liver Testing.
    N Engl J Med. 2023;388:544-554.
    PubMed    
    
    
    
26. JU H, Liu C
    Cerebral Alveolar Echinococcosis.
    N Engl J Med. 2023;388:453.
    PubMed    
    
    
    January 2023
27. GOYAL L, Meric-Bernstam F, Hollebecque A, Valle JW, et al
    Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma.
    N Engl J Med. 2023;388:228-239.
    PubMed     Abstract available
    
    
    December 2022
28. VIEDMA-MARTINEZ M, Villegas Romero I
    Skin Necrosis after Transarterial Chemoembolization.
    N Engl J Med. 2022;387:2268.
    PubMed    
    
    
    
29. OLYNYK JK, Ramm GA
    Hemochromatosis.
    N Engl J Med. 2022;387:2159-2170.
    PubMed    
    
    
    August 2022
30. STRNAD P, Mandorfer M, Choudhury G, Griffiths W, et al
    Fazirsiran for Liver Disease Associated with Alpha1-Antitrypsin Deficiency.
    N Engl J Med. 2022;387:514-524.
    PubMed     Abstract available
    
    
    July 2022
31. VERWEIJ N, Haas ME, Nielsen JB, Sosina OA, et al
    Germline Mutations in CIDEB and Protection against Liver Disease.
    N Engl J Med. 2022;387:332-344.
    PubMed     Abstract available
    
    
    January 2022
32. PATEL A, Tillman BF
    Spur-Cell Hemolytic Anemia.
    N Engl J Med. 2022;386:e6.
    PubMed    
    
    
    
33. SANYAL AJ, Van Natta ML, Tonascia J
    Nonalcoholic Fatty Liver Disease. Reply.
    N Engl J Med. 2022;386:296.
    PubMed    
    
    
    
34. FRANCQUE SM, Bedossa P, Abdelmalek MF
    Nonalcoholic Fatty Liver Disease. Reply.
    N Engl J Med. 2022;386:295-296.
    PubMed    
    
    
    
35. MIR BA, Majeed T, Chauhan A
    Nonalcoholic Fatty Liver Disease.
    N Engl J Med. 2022;386:295.
    PubMed    
    
    
    
36. XIA ML, Wang H
    Nonalcoholic Fatty Liver Disease.
    N Engl J Med. 2022;386:294-295.
    PubMed    
    
    
    
37. HORN P, Newsome PN
    Nonalcoholic Fatty Liver Disease.
    N Engl J Med. 2022;386:294.
    PubMed    
    
    
    December 2021
38. WILLETT LL, Bromberg GK, Chung R, Leaf RK, et al
    Case 38-2021: A 76-Year-Old Woman with Abdominal Pain, Weight Loss, and Memory Impairment.
    N Engl J Med. 2021;385:2378-2388.
    PubMed    
    
    
    November 2021
39. CHAPMAN MM, Muse VV, Mojica JE, Anahtar MN, et al
    Case 35-2021: A 50-Year-Old Woman with Pain in the Left Upper Quadrant and Hypoxemia.
    N Engl J Med. 2021;385:1995-2001.
    PubMed    
    
    
    October 2021
40. GARCIA-TSAO G
    Nonalcoholic Steatohepatitis - Opportunities and Challenges.
    N Engl J Med. 2021;385:1615-1617.
    PubMed    
    
    
    
41. SANYAL AJ, Van Natta ML, Clark J, Neuschwander-Tetri BA, et al
    Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease.
    N Engl J Med. 2021;385:1559-1569.
    PubMed     Abstract available
    
    
    
42. FRANCQUE SM, Bedossa P, Ratziu V, Anstee QM, et al
    A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH.
    N Engl J Med. 2021;385:1547-1558.
    PubMed     Abstract available
    
    
    September 2021
43. CHANDRA A, Bhattacharjee MS
    Kayser-Fleischer Rings in Wilson's Disease.
    N Engl J Med. 2021;385:e46.
    PubMed    
    
    
    
44. BAJAJ JS, Kamath PS, Reddy KR
    The Evolving Challenge of Infections in Cirrhosis. Reply.
    N Engl J Med. 2021;385:1151-1152.
    PubMed    
    
    
    
45. HAIDAR G, Singh N
    The Evolving Challenge of Infections in Cirrhosis.
    N Engl J Med. 2021;385:1150-1151.
    PubMed    
    
    
    August 2021
46. ZOU Q, Li Y
    Hypervirulent Klebsiella pneumoniae.
    N Engl J Med. 2021;385:833.
    PubMed    
    
    
    
47. FREDRICK TW, Neto MBB, Johnsrud DO, Camilleri M, et al
    Turning Purple with Pain.
    N Engl J Med. 2021;385:549-554.
    PubMed    
    
    
    July 2021
48. KELLEY RK, Greten TF
    Hepatocellular Carcinoma - Origins and Outcomes.
    N Engl J Med. 2021;385:280-282.
    PubMed    
    
    
    
49. BUTTERS CT, Nash M
    Infantile Hepatic Hemangiomas.
    N Engl J Med. 2021;385:e10.
    PubMed    
    
    
    
50. NEWSOME PN, Sejling AS, Sanyal AJ
    Semaglutide or Placebo for Nonalcoholic Steatohepatitis. Reply.
    N Engl J Med. 2021;385:e6.
    PubMed    
    
    
    
51. DA BL, Satapathy SK
    Semaglutide or Placebo for Nonalcoholic Steatohepatitis.
    N Engl J Med. 2021;385:e6.
    PubMed    
    
    
    June 2021
52. BAJAJ JS, Kamath PS, Reddy KR
    The Evolving Challenge of Infections in Cirrhosis.
    N Engl J Med. 2021;384:2317-2330.
    PubMed    
    
    
    
53. WONG F, Curry MP, Sanyal AJ
    Randomized Trials of Interventions for Hospitalized Patients with Cirrhosis. Reply.
    N Engl J Med. 2021;384:e90.
    PubMed    
    
    
    
54. CHINA L, Freemantle N, O'Brien A
    Randomized Trials of Interventions for Hospitalized Patients with Cirrhosis. Reply.
    N Engl J Med. 2021;384:e90.
    PubMed    
    
    
    
55. RATHI S, Kalantri A, Kalantri S
    Randomized Trials of Interventions for Hospitalized Patients with Cirrhosis.
    N Engl J Med. 2021;384:e90.
    PubMed    
    
    
    
56. CHAUHAN A, Sharma S, Saraya A
    Randomized Trials of Interventions for Hospitalized Patients with Cirrhosis.
    N Engl J Med. 2021;384:e90.
    PubMed    
    
    
    
57. ELFEKI MA, O'Shea R, Carey WD
    Randomized Trials of Interventions for Hospitalized Patients with Cirrhosis.
    N Engl J Med. 2021;384:e90.
    PubMed    
    
    
    April 2021
58. COHN A, Nehs M, Chan J, Vaidya A, et al
    Casting a Wide Net.
    N Engl J Med. 2021;384:e50.
    PubMed    
    
    
    
59. MCINNES IB, Anderson JK, Magrey M, Merola JF, et al
    Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis.
    N Engl J Med. 2021;384:1227-1239.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge.